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Abstract
Objective: To explore the feasibility of home monitoring of epilepsy patients with a 
novel subcutaneous electroencephalography (EEG) device, including clinical impli-
cations, safety, and compliance via the first real‐life test.
Methods: We implanted a beta‐version of the 24/7 EEG SubQ (UNEEG Medical 
A/S, Denmark) subcutaneously in nine participants with temporal lobe epilepsy. 
Data on seizures, adverse events, compliance in using the device, and use of antie-
pileptic drugs (AEDs) were collected. EEG was recorded for up to 3 months, and 
all EEG data were reviewed visually to identify electrographic seizures. These were 
descriptively compared to seizure counts and AED changes reported in diaries from 
the same period.
Results: Four hundred ninety days of EEG and 338 electrographic seizures were 
collected. Eight participants completed at least 9 weeks of home monitoring, while 
one cancelled participation after 4 weeks due to postimplantation soreness. In total, 
13 cases of device‐related adverse events were registered, none of them serious. 
Recordings obtained from the device covered 73% of the time, on average (range 
45%‐91%). Descriptively, electrographic seizure counts were substantially different 
from diary seizure counts. We uncovered several cases of underreporting and re-
vealed important information on AED response. Electrographic seizure counts re-
vealed circadian distributions of seizures not visible from seizure diaries.
Significance: The study shows that home monitoring for up to 3  months with a 
subcutaneous EEG device is feasible and well tolerated. No serious adverse device‐
related events were reported. An objective seizure count can be derived, which often 
differs substantially from self‐reported seizure counts. Larger clinical trials quantify-
ing the benefits of objective seizure counting should be a priority for future research 
as well as development of algorithms for automated review of data.
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1 |  INTRODUCTION
Epilepsy is a brain disorder characterized by recurrent sei-
zures. Thus, counting seizures is an essential part of track-
ing disease activity. Traditionally, patients record seizures 
in a seizure diary, but several studies show that such diaries 
are often unreliable.1‒3 Many factors contribute to this prob-
lem, with unrecognized and undocumented seizures being 
the most important.4,5 Because the seizure count is a deci-
sive factor in the choice of treatment, an imprecise seizure 
count could lead to suboptimal treatment with increased risk 
of complications. These clinical problems also concern the 
patients,6 and in the context of epilepsy research the problem 
of wrongful reporting is also well known.7
Objective and accurate seizure counting at home could be 
of great benefit in diagnosis, management, and research in 
epilepsy. An EEG acquisition system usable during everyday 
life could be the tool currently lacking in the toolbox of ep-
ilepsy diagnostics and management.8,9 Recently, many new 
EEG devices have appeared, combining various electrode 
configurations and data processing methods,10‒15 but none of 
these have been tested in real‐life. In this study, we present 
the first real‐life data on a subcutaneous EEG device for con-
tinuous home monitoring of epilepsy. In our previous study, 
we found this device comparable to traditional scalp EEG in 
a controlled environment.16 In this study, we provide data on 
safety and compliance, and compare detection of seizures be-
tween seizure diaries and the new device using descriptive 
methods. Finally, we discuss the clinical relevance of our data 
relating to other seizure‐detection devices.
2 |  METHODS
2.1 | Study design and participants
The study was conducted according to the Helsinki Declaration 
following guidelines for good clinical practice. The commit-
tee of science ethics for Region Zealand approved the study 
(SJ‐551). All participants provided written informed consent 
before any study activities were commenced. The study is 
registered in clinicalstrials.gov (NCT02946151).
The study was an exploratory, qualitative study. Patients 
from the outpatient epilepsy clinics were prescreened ac-
cording to our eligibility criteria at Zealand University 
hospital (ZUH) from 2017‐01‐01 to 2018‐10‐31 and 
Odense University Hospital (OUH) from 2018‐03‐01 to 
2018‐10‐31. Only adult patients with known or suspected 
temporal/frontotemporal seizure‐onset zone (as corrob-
orated by EEG or magnetic resonance imaging [MRI]) 
and self‐reported seizure frequency of at least one seizure 
per month were eligible. Exclusion criteria included any 
disorders or activities that might infer additional risk at 
participation or affect the quality of data. Patients with 
comorbid psychogenic nonepileptic seizures (PNES) were 
eligible only if they also had definite or probable genu-
ine epilepsy fulfilling the inclusion criteria, and the gen-
uine seizures were assessed to constitute a majority. All 
eligibility criteria are presented in Appendix S1. Due to 
limitations imposed by national data regulations, we had 
to pre‐screen 1421 unselected patients referred to the ep-
ilepsy clinics. The main reasons for exclusion were as 
follows: lack of radiologic/electrographic corroboration 
of seizure‐onset zone and treatment with anticoagulants/
antiplatelets. Some patients met more than one exclusion 
criteria, but only the one considered the most important 
was documented. Figure S1 provides a flowchart of both 
the screening process and the study visits. Based on our 
eligibility criteria, 20 patients were invited for further in-
formation. Of these, three potential participants found the 
device too obtrusive, and declined to participate. Four de-
clined, as they were preoccupied with intensive diagnostic 
workups in an epilepsy surgery program, and three were 
precluded from participation by the investigator as they 
were found unlikely to be able to complete the study proto-
col due to social or mental issues. In total, 10 participants 
were included, of whom 9 were implanted. Participants 
were scheduled to use the subcutaneous EEG device for 
approximately 3 months with no restrictions on activities, 
except from the eligibility criteria. Because monitoring du-
ration by far exceeds that of traditional long‐term monitor-
ing, we henceforth refer to monitoring times exceeding 1 
month as “ultra‐long‐term monitoring.” After completing 
the study, participants continued their customary follow‐up 
in the outpatient epilepsy clinic.
2.2 | The device
The novel EEG acquisition system consists of an EEG elec-
trode designed for subcutaneous implantation (termed “the 
implant”) and an external logging device for power supply 
and data transfer (termed “the external logging device,” 
ELD). The implant has three leads (one reference, two active) 
resulting in two bipolar channels recording at 207 Hz. The 
Key Points
• First trial on subcutaneous electroencephalography 
(EEG) home monitoring over several months
• Subcutaneous EEG is feasible and well tolerated
• Subcutaneous EEG recordings can provide an ob-
jective seizure count
• Development of validated algorithms for automated 
review is the next step
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implant and ELD together will be referred to as “the SubQ 
system.”
Surgical procedures were performed under local an-
esthesia by a surgeon who had undergone video training. 
In brief, a short incision (approximately 3 cm) was made 
behind the ear and the electrode was tunneled approxi-
mately 10 centimeters subcutaneously parallel to the tem-
poral lobe. A small subcutaneous pocket was made to host 
the house of the electrode. The subcutis was sutured with 
resorbable suture (Vicryl 4‐0) and cutis was sutured with 
Nylon (4‐0). After approximately 10 days, the transceiver 
was attached to the skin by double‐sided adhesive pads 
and the ELD itself was attached to the clothing by a strong 
magnet. The ELD used in the study was a beta version of 
the 24/7 EEG SubQ produced by UNEEG Medical A/S. 
Figure S2 shows the ELD in vivo. The system and surgical 
procedures have previously been described in greater detail 
in our proof‐of‐concept study.16
2.3 | Data collection and analysis
2.3.1 | Usage, adverse events, antiepileptic 
drugs, and self‐reported seizures
Participants were instructed to wear the ELD all the time, ex-
cept during bathing/showering or similar activities. Data on 
usage times for each participant were derived from the time 
stamps and duration of the recorded EEGs as saved by the 
ELD. MATLAB R2018a (MathWorks) was used to create 
the visual presentations.
Adverse device events (ADEs) were defined as any unin-
tended or unfavorable response to the system during the study 
period possibly related to the use of the device or related pro-
cedures. We classified all ADEs according to severity based 
on their impact on daily life as the following: mild (does not 
interfere with everyday activities), moderate (interferes with 
some everyday activities), and severe (prevents some every-
day activities). Serious ADEs were defined as ADEs requir-
ing hospitalization, leading to death (or would have done so 
in the absence of treatment), congenital anomalies, or lasting 
disability. These definitions were preset prior to the com-
mencement of the study.
Data on the use of antiepileptic drugs (AEDs) were col-
lected at every study visit. Commencement, adjustments, and 
discontinuation of AEDs were noted.
Participants were instructed to document all events that 
they believed to be seizures in a seizure diary. The seizure 
diary was available either as an app or in a paper form. In 
the app, collection of the time and date was integrated with 
the registration of each event. In the paper form, participants 
had to note time and date by themselves. Participants were 
also instructed to provide a detailed seizure description form 
(Appendix S2).
Family members or caregivers were also allowed to fill 
out the seizure description forms. Upon collection, the par-
ticipants had an opportunity to comment on the entries to the 
seizure diary and the seizure descriptions. Based on all the 
information available, self‐reported events were categorized 
into a two‐step process. First we evaluated whether each entry 
was an epileptic seizure at all and labeled each self‐reported 
event as probably epileptic or nonepileptic seizures. Second, 
we evaluated each epileptic seizure and added a further semi-
ology label as “focal aware seizure (FAS),” “focal impaired 
awareness seizure (FIAS),” or “uncertain.” This distinction 
was made by an experienced epileptologist (S.W.).
2.3.2 | EEG analysis
Prior to the review of the collected EEG data, all available 
previous scalp EEG recordings and/or reports for each par-
ticipant were thoroughly reviewed to establish one or more 
personal spectrographic seizure signatures (henceforth sim-
ply referred to as a “seizure signature”), under the assump-
tion that each seizure type in each participant had a unique 
signature. We then reviewed all the EEG data from the SubQ 
system by visual inspection of time‐frequency spectrograms. 
We relied on the built‐in spectrograms of the EEG reader, 
which utilizes a fast Fourier transformation (1‐second reso-
lution, Hamming window, 50% overlap). Figure 1 shows a 
screenshot of a seizure signature and the corresponding raw 
EEG presented in the same way we reviewed data.
Duration of the spectrogram shown on the screen was set 
at 10 minutes and the frequency scale from 0 to 30 Hz. These 
settings were selected as a trade‐off between analysis speed 
and level of detail visible. Whenever the predefined signature 
was identified, we reviewed the event in the time domain to 
confirm or reject the event as a seizure and made a seizure 
annotation if relevant. We also reviewed the raw EEG if any 
other unusual spectrographic pattern appeared. By default, we 
reviewed 5 minutes of raw EEG before and after any event, 
but if circumstances dictated it, we reviewed as much as 
needed to make a decision. The entire review was performed 
by a trained epileptologist with several years of experience 
in visual EEG review (S.W.) using Nervus EEG Reader v. 
5.95. All seizure annotations underwent secondary review 
by a board‐certified neurophysiologist (T.W.K.), who made 
the final ruling. To avoid expectation bias, this procedure was 
performed before self‐reported events were evaluated.
After the evaluation of self‐reported events, we reviewed 
the time domain EEG of two examples of each kind of prob-
able epileptic seizure reported by each participant, to ensure 
that no such self‐reported events had an electrographic equiv-
alent that was visible only in the time domain but not in the 
spectrograms.
For visualization of the circadian distribution of electro-
graphic seizures, we binned the time stamps of all seizures 
   | 2207WEISDORF Et al.
in 3‐hour bins for each participant. For this analysis, we 
excluded all participants with fewer than 16 electrographic 
seizures, as we considered this the minimum requirement to 
discern any possible rhythmicity reliably.
In anticipation of considerable contamination of the EEG 
signal by electromyography (EMG) artifacts from the activity 
of the temporal muscles, we conceptualized high frequency 
noise as the EEG power above 20 Hz. We then visualized the 
signal‐to‐noise ratio (SNR) as: Ptotal signal/Pnoise, with P 
being the power. This allowed us the estimate the effect of 
noise on seizure detection descriptively.
3 |  RESULTS
We included 10 participants in the study. Eight partici-
pants completed the study according to protocol. One par-
ticipant dropped out of the study before implantation for 
personal reasons and therefore provided no recordings; that 
participant is disregarded henceforth. One participant (ID 
A) dropped out of the study after 1 month due to discom-
fort from the implant. The mean age of participants was 
43.7 years (range 27‐64). There were two male and seven 
female participants who provided recordings. All partici-
pants except participant B, who was recently diagnosed, 
were medically refractory. No participants were involved 
in epilepsy surgery programs while using the SubQ system. 
Further characteristics of the participants and events of in-
terest are summarized in Table 1.
Participants B and F are particularly noteworthy. They re-
ported events with normal awareness only and a substantial 
number of these events had no electrographic equivalent. 
Unfortunately, the lack of seizure‐by‐seizure time matching 
of electrographic and self‐reported seizures prohibits statis-
tical testing.
3.1 | Compliance and noise
We recorded 11 774 hours (490.6 days) of EEG of a possible 
16 147 hours (73%). Participant C stopped using the ELD 
at night after approximately 1 month because he preferred 
sleeping undressed and the ELD requires clothing for attach-
ment. This has taken a great toll on the overall compliance. 
The compliance of the participants along with the SNR and 
seizures is shown in Figure 2. For most participants, it can 
be seen how SNR decreases during the daytime but nonethe-
less, many electrographic seizures were detected.
3.2 | Seizure comparison
The visual review to identify electrographic seizures took 
one trained researcher approximately 3 months to perform. 
In all participants, except participant A, who had no sei-
zures on record, definite signatures could be established, 
and we identified no seizures with incongruence between 
time domain and spectrogram. Two participants used the 
app for documentation of self‐reported seizures and seven 
participants opted to use the analogue diary. In most ana-
logue diaries participants frequently failed to provide sei-
zure times (providing only dates). Therefore, we tabulated 
self‐reported events by date only. Figure  3 shows self‐
reported probable epileptic seizures and electrographic 
F I G U R E  1  Seizure signature. The top panel shows the spectrograms of the two subcutaneous channels (DSQ‐CSQ; PSQ‐CSQ) as reviewed 
in the study. The yellow square highlights the spectrographic seizure signature, which, in this case, can be discerned only on spectrogram 
PSQ‐CSQ. For each type of seizure from each participant, one signature was predefined from previous scalp electroencephalography (EEG) 
recordings. Shortly after the seizure, there is an increase in delta power (0.5‐4 Hz), which could represent a postictal EEG pattern. Any 
spectrographic pattern resembling the relevant signature would be reviewed in the time domain for confirmation. The bottom panel shows the raw 
EEG at the time of the seizure with rhythmic theta activity in channel PSQ‐CSQ and typical frequency dynamics. Thus, the raw EEG confirms the 
presence of a seizure
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seizures. Participants D and E had a substantial number 
of electrographic seizures without corresponding diary 
entries. In contrast, participants B and F had many diary 
entries without corresponding electrographic seizures. 
Participant I had both electrographic seizures without diary 
entries and vice versa. Participants A, C, and H had few 
events of any kind. For participant G there is almost com-
plete congruence between self‐reported and electrographic 
seizures.
Due to the limited number of participants, we did not per-
form hypothesis testing statistics.
For participant D, the commencement of perampanel treat-
ment seems to reduce the number of self‐ reported seizures, 
whereas the electrographic seizure count seems to increase. 
For participant E, the electrographic seizure count seems to 
decrease after treatment is started. Participants C and F had 
too few electrographic seizures to establish a reliable pattern.
Concerning electrographic seizures, participants B, C, D, 
G, and I seem to have circadian rhythms based on Figure 3, 
but participants C and G have too few seizures to establish 
a trustworthy pattern. For participants with enough seizures 
(≥16), histograms of the electrographic seizures plotted 
against the time of day are shown in Figure 4, and this con-
firms the impression of rhythmicity. Participant E does not 
have any apparent circadian rhythmicity.
3.3 | Adverse events
No serious ADEs were reported and all the ADEs reported 
were anticipated, except one (“unclassified”). Table 2 sum-
marizes all ADEs.
As expected, most participants experienced soreness at 
the implantation site after the surgery. For six participants, 
this soreness receded within approximately 1 week; one par-
ticipant reported no soreness at all. Two had longer‐lasting 
soreness, for 2  weeks and 4  weeks, respectively. Soreness 
after explantation receded within a few days in all cases.
Two participants reported occasional headaches during 
the study. For one, the reported headaches were mild and did 
not require any response. For the other, the headaches were 
of moderate intensity and required over‐the‐counter pharma-
cologic treatment; in this case, the participant had also had 
occasional headaches prior to inclusion to the study. The 
headaches were similar in frequency and intensity before and 
during the study.
Two participants experienced minor irritation of the skin 
where the transceiver was attached; this was ameliorated by 
detaching the transceiver for short periods.
The unclassified event was described as a tingling sensa-
tion in the implant, but only when located at certain places 
in her house. Technical examinations of the implant after ex-
plantation revealed no malfunctions.
3.4 | User experience
Information on user experiences was collected only anecdo-
tally. Most participants found the ELD easy to use and had 
no problems with the daily operations. Minor annoyances 
were noted, such as occasional nightly disconnections, hav-
ing to adjust the usual position of glasses, and the necessity 
of wearing clothes at night. No participants felt constrained 
in their ability to perform jobs or leisure activities.
4 |  DISCUSSION
This study is the first to describe ultra long‐term monitoring 
of epilepsy patients with a minimally invasive EEG system 
in a real‐life setting anywhere in the world. We have shown 
that home monitoring for approximately 3 months is feasible 
ID
Onset 
zone Semiologya 
Self‐reported 
eventsb (epileptic; 
nonepileptic)
Electrographical 
seizures
Employment 
status
A LT FAS 0; 3 0 Unemployed
B LT FAS 55; 0 22 Unemployed
C RT FIAS with FBTCS 0; 3 5 Employed
D RFT FAS and FIAS 32; 0 232 Unemployed
E LT FIAS with FBTCS 0; 2 16 Employed
F LT FAS 21; 0 3 Employed
G LT Uncertain 13; 11 12 Employed
H LT FIAS with FBTCS 1; 5 2 Unemployed
I LT FIAS with FBTCS 133; 43 46 Employed
Abbreviations: FAS, focal aware seizure; FBTCS, focal to bilateral tonic‐clonic seizure; FIAS, focal impaired 
awareness seizure; LT, left temporal; RFT, right frontotemporal; RT, right temporal.
aObserved by participant or family/caregivers. 
bClassification by investigator. 
T A B L E  1  Participant characteristics
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without major adverse events or significant impact on activi-
ties of daily living. Total compliance was moderate (73%) 
with high interindividual variability (45%‐91%). This vari-
ability was not related to adverse events but seemed to depend 
on everyday practicalities and hardware usability. The clinical 
implications of compliance issues should not be underesti-
mated, and it warrants careful patient selection and thorough 
information about all parts of the SubQ system. For some par-
ticipants, the electrographic seizures detected showed clear 
circadian rhythmicity. This is well in line with the findings 
published by Baud et  al.17 Qualitatively, the objective sei-
zure count provided information on participants’ response 
to changes in AEDs that would not have been revealed from 
the seizure diaries. Such information could affect the choice 
of treatment. Participants reported minimal impact on daily 
activities.
The participants are examples of clinical cases in 
which the information provided by the ultra long‐term 
F I G U R E  2  User compliance and signal‐to‐noise ratio. Charts for all participants displaying their compliance in using the external logging 
part of the device across the full study period by time of day. Total percentage for each participant in parentheses. Gray areas display epochs when 
the ELD was not used. No pattern of increased detection of electrographic seizures is apparent, suggesting that a detection bias due to noise is less 
plausible
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EEG would probably influence the treatment strategy. 
Controversially, we considered the electrographic sei-
zures to be the ground truth and taking that into account, 
participants C, D, and E are cases of underreporting. The 
diary information alone would present the seizure burden 
as lower than it was. This could lead to a more passive 
treatment strategy, thereby increasing the risk of compli-
cations related to repeated seizures. All these participants 
had focal seizures with impaired awareness, which is a 
likely cause of the underreporting.
Participants B and F are seemingly cases of overreporting. 
These two participants had seizures with normal awareness, 
which is usually taken as an indication that a smaller cortical 
area has been involved in the abnormal activity. The precise 
area of cortical surface necessary for a seizure to be detected 
by electrodes placed outside the skull depends on many fac-
tors, but several studies have shown that smaller cortical sur-
face involvement decreases the chance of detecting epileptic 
discharges using scalp electrodes.18‒20 It seems likely that 
the same limitation applies to subcutaneous electrodes, such 
F I G U R E  3  Seizure comparison and antiepileptic drugs. Charts for all participants showing electrographic seizures and self‐reported events 
classified as probable epileptic seizures. Self‐reported events are semiquantified and displayed by date only. Electrographic seizures are displayed 
by time of day. Changes in antiepileptic medication are shown on top of each chart. Participant E is a good example of underreporting, as she 
reported none of the electrographic seizures. BRV, brivaracetam; CLB, clobazam; LCM, lacosamide; LEV, levetiracetam; LTG, lamotrigine; PER, 
perampanel; ZNS, zonisamide
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as the implant we tested. Therefore, we cannot say whether 
the self‐reported events of these two participants are true sei-
zures or not, without ambiguity. In the field of seizure‐detec-
tion devices, overreporting of seizures seems to have received 
less attention than underreporting, but in our opinion, it is 
equally important. PNES could be considered a kind of over-
reporting, in which there is a great need for new diagnostic 
tools. Overreporting is more likely to lead to overtreatment 
and it holds risks of more adverse effects and interactions 
from AEDs.
Participant I was unique among our subjects. She mis-
reported in a way that involved both underreporting and 
overreporting. The electrographic seizure count revealed 
a very different pattern of seizure activity than the self‐re-
ported seizures. Such findings could be of great importance 
in uncovering potential seizure‐precipitating factors, such as 
sleep deprivation or AED oversights.
Participant G was the only one among the included pa-
tients who was able to report her own seizures reliably, as 
seen by the high concordance between diary entries and elec-
trographic seizures.
To the authors’ knowledge, there are no equivalent 
devices at the same stage of development. Several other 
seizure‐detection devices have appeared within the last de-
cade, some employing EEG2,10,17,21,22 and some employing 
other technologies, such as EMG/accelerometry,23,24 heart 
rate variability,25 electrodermal activity, or a combination 
of these.26,27 Describing the influence of an ultra‐long‐term 
EEG monitoring device on the mobility of the wearer is a 
key aspect of its usability. In 2017, Bateson et al28 devel-
oped a mobility score for use in wearable EEG research 
going from 0 (least mobile) to 5 (most mobile). The device 
we tested does not exactly fit into the existing categories, 
but given the minimal impact on mobility, we assess it at a 
score of 4‐5. Combined with the ease of use and minimal 
invasiveness, this makes for a very favorable usability pro-
file for this system.
4.1 | Limitations
The present study had some shortcomings that must be con-
sidered when discussing the results. Several of these relate to 
the electrographic seizures.
First, we reviewed spectrograms rather than raw EEG. 
This was necessary to expedite the analysis, which even by 
this method took several months to perform. The process was 
monotonous, leaving room for human error due to lapses of 
attention. Reviewing the raw EEG would have exacerbated 
this problem, but also allowed for a more detailed analysis 
and we cannot exclude the possibility that reviewing the raw 
F I G U R E  4  Circadian distribution of electrographic seizures. 
Histograms showing the circadian distribution of electrographic 
seizures for participants with ≥16 seizures. Days are divided into 3‐h 
bins. All the presented participants, except participant E, seems to have 
a circadian pattern to their seizures
Event type
No. of 
occurrences Severity Anticipated
Pain/soreness at site of surgery up to 1 
week after surgery
6 Mild Yes
Pain/soreness at site of surgery more 
than 1 week after surgery
2 Mild Yes
Headache not related to surgery 2 Mild Yes
Skin irritation at transceiver contact 
position
2 Mild Yes
Excessive bleeding 0 — —
Infection 0 — —
Unclassified 1 Mild No
T A B L E  2  Summary of adverse device 
events
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EEG would have yielded slightly different results. Second, 
there are some cases in which a true seizure could have oc-
curred without being detected by the device:
1.  The seizure did not involve a large enough cortical 
area to be visible in extracranial recordings of any kind.
2.  The seizure did not propagate to a cortical area below the 
implant and was therefore not recorded.
3.  The electrographic presentation of the seizure was dis-
creet and would have required more spatial information to 
be detectable.
4.  The electrographic seizure was not visible due to artifacts.
Although we took every precaution to avoid these issues by 
carefully selecting the participants and reviewing our data thor-
oughly, they might have occurred, adding a measure of impre-
cision to our electrographic seizure count. Participants B and 
F are examples of cases in whom we suspect these limitations 
influenced the electrographic seizure count. For statistical con-
firmation of this suspicion, we would have needed self‐reported 
seizures with a precise time stamp for comparison with the 
electrographic seizures, which we did not have. Digital seizure 
diaries facilitate a more precise documentation of self‐reported 
events, and we hope that the use of such diaries will grow more 
common in the future.
Validation of electrographic seizures is an obstacle that 
will require a major setup, preferably one employing intra-
cranial EEG electrodes. Several studies have shown that in-
tracranial electrodes, if positioned correctly in relation to the 
seizure focus, can be used to detect more seizures than scalp 
EEG electrodes.29‒32 It seems likely that this relationship ex-
tends to subcutaneous electrodes, since the skull attenuates 
the EEG signal more than the other scalp tissue layers.33An-
other way to get around this problem is to perform large‐scale 
trials comparing clinical outcomes for groups of patients in 
whom decision‐making was based on traditional methods 
to other groups in whom decision‐making was informed by 
whatever method in question. Such trials would be long and 
complicated, but also very informative. Recently, a proposal 
for standards for clinical trials of medical devices was pre-
sented.34 Such standards should guide future studies on novel 
seizure‐detection devices to facilitate comparison between 
studies and meta‐analyses.
Using automated seizure detection algorithms would 
have been a very attractive solution for review of the massive 
amounts of data we collected. Such algorithms have been 
successfully employed previously in ultra‐long‐term moni-
toring scenarios35 However, automated algorithms must be 
validated properly to be reliable, and no algorithms had been 
validated properly on subcutaneous EEG when our dataset 
was ready for review.
Unfortunately, comparing detection of seizures from 
scalp EEG recordings and subcutaneous recordings during 
the epilepsy monitoring unit (EMU) admission was not pos-
sible. This was due to the electrographically subtle seizures 
from participant D, which constituted most of the seizures 
recorded during admission; any comparison would have re-
flected the unusual electrographic presentation of the sei-
zures, rather than any features of the devices compared.
Other limitations are the low number of participants in 
our study and the fact that we focused on persons with tem-
poral lobe epilepsy. These decisions, although necessary for 
the feasibility of the study, decrease the generalizability of 
our findings. Despite this, the current study provides crucial 
safety and usability data, and the data we collected may be 
used to form hypotheses in future studies.
Finally, artifacts contaminated parts of our data, espe-
cially during the daytime. Considering the proximity of the 
implant to the temporal and mastoid muscles, this was an-
ticipated. Potentially, artifacts could obscure the detection 
of electrographic seizures and thereby introduce a bias to 
our findings on circadian rhythmicity and our comparison 
of electrographic and self‐reported seizures. Our findings, 
though, do not show a general preponderance of electro-
graphic seizures during the nighttime, when the SNR is 
the highest, which seems to indicate that any potential bias 
in the detection of electrographic seizures is not severe. 
Methods for artifact rejection, both through improved sur-
gical techniques and postprocessing of the electrographic 
data, should be explored further.
In conclusion, this is the first study to demonstrate that ultra 
long‐term epilepsy home monitoring based on recordings from 
a minimally invasive, subcutaneous implant is feasible and safe. 
During almost 500 days of home monitoring, no serious ADEs 
occurred. Before implementing ultra long‐term home monitor-
ing EEG systems in clinical practice, larger trials with clinically 
relevant outcome measures are needed. In addition, algorithms 
for automated analysis of ultra long‐term EEGs are an abso-
lute necessity, as traditional visual analysis is both immensely 
time‐consuming and a victim of subjectivity. Nonetheless, there 
seem to be several clinical scenarios for which the information 
yielded by such monitoring could provide better treatment and 
despite the limitations, we believe that devices for minimally 
invasive ultra‐long‐term monitoring will be an important con-
tribution to the neurophysiology toolbox.
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